SV Life Sciences has raised the year’s second-largest life sciences fund thus far, exceeding its targeted amount to close with $523 million in commitments.
The firm had originally planned to raise $400 million, but attributed its fundraising success in today’s “challenging environment” to its past success, according to a statement.
SV’s fundraise represents the second-largest of the year among life sciences funds, trailing only OrbiMed Advisor’s $550 million, the Wall Street Journal reported.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
SV’s portfolio companies include Ricerca Biosciences, a Concord Township, Ohio-based contract drug development company, and Entellus Medical, a Maple Grove, Minn.-based developer of a sinusitis-treating device.
The fund is expected to invest in companies involved in a number of healthcare sectors, such as biotechnology and pharmaceuticals, medical devices, health services and health information technology. Investments will generally range from $5 million to $35 million, according to the statement.
The firm also sees opportunity in swooping in to fund companies whose existing investors are struggling financially, Chairman James Garvey told the Journal. “It lets us be on the right side of the Darwinian equation,” he said. “We think that the weaker firms will get flushed out.”
SV’s impressive fundraise suggests it will be one of the survivors as those less-capitalized firms die off in an anticipated industry shake-up that many observers expect will happen in coming years. Ten-year venture capital returns have fallen in recent years, as the once-lucrative IPO market has slowed and technology startups no longer need as much capital as they once did to get rolling. That’s led to much hand-wringing in recent years about the venture model being “broken.”
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Approximately 60 percent of SV’s capital commitments came from the United States and 40 percent from Europe and the rest of the world. The latest fundraise brings the firm’s capital under management to about $2 billion. In addition to Boston, SV has offices in San Francisco and London.
